Cardium Therapeutics

Welcome to Cardium Therapeutics confidential, anonymous web submission system provided by Thomson Reuters. We are committed to complying with section 301(4) of the Sarbanes-Oxley Act of 2002. This confidential reporting system has been established for the receipt, retention, and treatment of complaints received by Cardium Therapeutics regarding accounting, internal accounting controls, or auditing matters, as well as violations of our Code of Conduct and Ethics. All submissions are made anonymously if that option is selected and will be directed to the appropriate individual(s) within the Company.

Cardium Therapeutics is committed to the highest standards of ethical conduct in its financial affairs and reporting. In accordance with applicable law, persons who in good faith report evidence of known or suspected fraud, theft, accounting or auditing improprieties, or other financial misconduct will not be retaliated against because of such reports.